BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of ILS 42.42 million. The enterprise value is 25.95 million.

Market Cap	42.42M
Enterprise Value	25.95M

Important Dates

The next estimated earnings date is Sunday, May 25, 2025.

Earnings Date	May 25, 2025
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 2.23 billion shares outstanding. The number of shares has increased by 24.37% in one year.

Current Share Class	n/a
Shares Outstanding	2.23B
Shares Change (YoY)	+24.37%
Shares Change (QoQ)	+9.05%
Owned by Insiders (%)	0.19%
Owned by Institutions (%)	4.68%
Float	2.13B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.40
PB Ratio	0.87
P/TBV Ratio	3.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.77
EV / Sales	0.25
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.16

Financial Position

The company has a current ratio of 1.76, with a Debt / Equity ratio of 1.12.

Current Ratio	1.76
Quick Ratio	1.52
Debt / Equity	1.12
Debt / EBITDA	n/a
Debt / FCF	-0.34
Interest Coverage	-2.11

Financial Efficiency

Return on equity (ROE) is -69.11% and return on invested capital (ROIC) is -44.90%.

Return on Equity (ROE)	-69.11%
Return on Assets (ROA)	-23.28%
Return on Invested Capital (ROIC)	-44.90%
Return on Capital Employed (ROCE)	-81.50%
Revenue Per Employee	3.76M
Profits Per Employee	-1.20M
Employee Count	28
Asset Turnover	0.56
Inventory Turnover	3.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -89.22% in the last 52 weeks. The beta is 0.86, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-89.22%
50-Day Moving Average	1.93
200-Day Moving Average	8.08
Relative Strength Index (RSI)	47.46
Average Volume (20 Days)	5,452,833

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioLineRx had revenue of ILS 105.41 million and -33.59 million in losses. Loss per share was -0.03.

Revenue	105.41M
Gross Profit	71.67M
Operating Income	-69.76M
Pretax Income	-33.59M
Net Income	-33.59M
EBITDA	-57.18M
EBIT	-69.76M
Loss Per Share	-0.03

Full Income Statement

Balance Sheet

The company has 71.25 million in cash and 54.78 million in debt, giving a net cash position of 16.47 million or 0.01 per share.

Cash & Cash Equivalents	71.25M
Total Debt	54.78M
Net Cash	16.47M
Net Cash Per Share	0.01
Equity (Book Value)	49.03M
Book Value Per Share	0.04
Working Capital	42.61M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -159.80 million and capital expenditures -193,042, giving a free cash flow of -159.99 million.

Operating Cash Flow	-159.80M
Capital Expenditures	-193,042
Free Cash Flow	-159.99M
FCF Per Share	-0.07

Full Cash Flow Statement

Margins

Gross margin is 67.99%, with operating and profit margins of -66.18% and -31.86%.

Gross Margin	67.99%
Operating Margin	-66.18%
Pretax Margin	-31.86%
Profit Margin	-31.86%
EBITDA Margin	-54.25%
EBIT Margin	-66.18%
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.37%
Shareholder Yield	-24.37%
Earnings Yield	-79.18%
FCF Yield	-377.17%

Stock Splits

The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.

Last Split Date	Jun 7, 2015
Split Type	Reverse
Split Ratio	0.1

Scores

BioLineRx has an Altman Z-Score of -13.48. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.48
Piotroski F-Score	n/a